INCY vs RMD: fair value comparison
Incyte Corporation and ResMed Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, RMD currently sits closer to the top of our ranking by discount to fair value.
| INCY | RMD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $112.79 | $230.05 |
| 12-month range | $90.18–$129.93 | $182.82–$275.96 |
| Rank by discount to fair value | #23 of 108 Healthcare | #18 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: INCY fair value analysis · RMD fair value analysis